Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun 17:7:485-90.
doi: 10.2147/DDDT.S43470. Print 2013.

Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration

Paris Tranos  1 , Athanasios Vacalis, Solon Asteriadis, Stavrenia Koukoula, Athanasios Vachtsevanos, Georgia Perganta, Ilias Georgalas
Affiliations
Review

Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration

Paris Tranos et al. Drug Des Devel Ther. .

Abstract

Age-related macular degeneration (AMD) is the main cause of visual impairment and blindness in people aged over 65 years in developed countries. Vascular endothelial growth factor (VEGF) is a positive regulator of angiogenesis and its proven role in the pathological neovascularization in wet AMD has provided evidence for the use of anti-VEGF agents as potential therapies. In this study, we review the literature for the possible causes of failure after treatment with anti-VEGF agents and attempt to propose an algorithm of suggestive actions to increase the chances of successful management of such difficult cases.

Keywords: age related macular degeneration; antiVEGF; treatment.

PubMed Disclaimer

References

    1. Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol. 1977;106:17–32. - PubMed
    1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy The Beaver Dam Eye Study. Ophthalmology. 1992;99:933–943. - PubMed
    1. Klein BE, Klein R. Cataracts and macular degeneration in older Americans. Arch Ophthalmol. 1982;100:571–573. - PubMed
    1. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology. 1995;102:1450–1460. - PubMed
    1. Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–676. - PubMed

MeSH terms

Substances